• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Diabetes, High Blood Pressure Raise Odds of COVID Harming Brain
MONDAY, Nov. 30, 2020 -- COVID-19 patients with high blood pressure or diabetes may be more likely to develop critical neurological complications, including bleeding in the brain and stroke, according to an ongoing study. University of Pennsylvania...
Source: Drugs.com - Daily MedNews - November 30, 2020 Category: General Medicine Source Type: news

Depression Is More than a Stigma
Manoj K. Pandey is Lecturer in Economics, Australian National University; Vani S. Kulkarni is Lecturer in Sociology, University of Pennsylvania; and Raghav Gaiha is (Hon. ) Professorial Research Fellow, Global Development Institute, University of ManchesterBy Manoj K. Pandey, Vani S. Kulkarni and Raghav GaihaCanberra, Philadelphia and Manchester, Mar 20 2019 (IPS) Depression is often distinguished from other non-communicable diseases or NCDs (e.g., cancer, diabetes, cardio-vascular diseases, hypertension) because of the stigma attached to it. Among other consequences, those suffering from depression are often denied access...
Source: IPS Inter Press Service - Health - March 20, 2019 Category: International Medicine & Public Health Authors: Manoj K. Pandey - and Raghav Gaiha Tags: Featured Global Headlines Health Human Rights TerraViva United Nations Women's Health Source Type: news

EuroPCR 2018 Roundup: Medtronic touts BP reductions, no major adverse events in renal denervation trial
Medtronic (NYSE:MDT) today released six-month results from a trial of its Symplicity Spyral renal denervation system exploring its use treating hypertensive patients who are already taking anti-hypertension medications, touting significant reductions in blood pressure and no major adverse safety events. Results were presented at the 2018 EuroPCR annual meeting in Paris and were published in The Lancet. In the trial, patients were prescribed up to three anti-hypertensive medications, including diuretics, calcium channel blockers, ACE/ARB inhibitors or beta blockers, the Fridley, Minn.-based company said. Patients were then...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Cardiac Implants Cardiovascular Clinical Trials Abbott Medtronic ReCor Medical Source Type: news

Falling off the health-care radar
Vani S. Kulkarni is a Lecturer in Sociology, University of Pennsylvania, U.S.; Raghav Gaiha is (Hon.) Professorial Research Fellow, Global Development Institute, University of Manchester, U.K.By Vani S. Kulkarni and Raghav GaihaPHILADELPHIA and NEW DELHI, Sep 28 2017 (IPS)Care for the elderly needs to be better targeted by the health system and social networks. The National Health Policy (NHP), 2017 is unable to see the wood for the trees. Life and death questions are dealt with perfunctorily or simply overlooked. For example, it overlooks the rapid rise in the share of the old (60 years or more), and associated morbiditie...
Source: IPS Inter Press Service - Health - September 28, 2017 Category: International Medicine & Public Health Authors: S Kulkami Tags: Aid Asia-Pacific Headlines Health Human Rights TerraViva United Nations Source Type: news

Care for the elderly needs to be better targeted by the health system and social networks
Vani S. Kulkarni is a Lecturer in Sociology, University of Pennsylvania, U.S.; Raghav Gaiha is (Hon.) Professorial Research Fellow, Global Development Institute, University of Manchester, U.K.By Vani S. Kulkarni and Raghav GaihaPHILADELPHIA and NEW DELHI, Sep 28 2017 (IPS)The National Health Policy (NHP), 2017 is unable to see the wood for the trees. Life and death questions are dealt with perfunctorily or simply overlooked. For example, it overlooks the rapid rise in the share of the old (60 years or more), and associated morbidities, especially sharply rising non-communicable diseases (NCDs) and disabilities. With rising...
Source: IPS Inter Press Service - Health - September 28, 2017 Category: International Medicine & Public Health Authors: S Kulkami Tags: Aid Asia-Pacific Headlines Health Human Rights Source Type: news

Medtronic readies pivotal trial in renal denervation
Medtronic (NYSE:MDT) said today that it’s ready for a run at FDA approval for renal denervation in treating high blood pressure, more than three years after the failure of a high-profile clinical trial. Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity HTN-3 trial, examining ablation of the around the renal arteries in treating hypertension, failed to meet its efficacy endpoint. The company suspended enrollment in its other Symplicity trials around the world and later took a $200 million write-down on its renal denervation assets. News of th...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Wall Street Beat Medtronic Renal Source Type: news